NC, United States of America

Talecris Biotherapeutics, Inc.


USPTO Granted Patents = 6

% Expired Patents = 50.0


Trademarks = 12

Forward Citations = 46

Loading Chart...
Loading Chart...

26 inventors (with patents filed for the assignee):

goldMedal Valery Novokhatny (3 out of 12 patents)

silverMedal Thomas P Zimmerman (2 out of 14 patents)

bronzeMedal Gary J Jesmok (2 out of 8 patents)

4.  Kyle A Landskroner (2 out of 3 patents)

5.  James Rebbeor (1 out of 8 patents)

6.  Ulrich Betz (1 out of 11 patents)

7.  Shan Jiang (1 out of 8 patents)

8.  Jonathan S Strauss (1 out of 5 patents)

9.  Jörg Kauling (1 out of 9 patents)

10.  Hans-Jürgen Henzler (1 out of 7 patents)

11.  Klaus Kaiser (1 out of 5 patents)

12.  Stephan Kirchner (1 out of 2 patents)

13.  Dirk Havekost (1 out of 4 patents)

14.  Jeffrey A Yuziuk (1 out of 2 patents)

15.  Richard Pasquinelli (1 out of 1 patent)


6 patents:

Company Overview
Talecris Biotherapeutics, Inc. is a global biotherapeutic company that discovers, develops, and produces critical care treatments for people with life-threatening conditions. Their mission is to improve the lives of patients by providing innovative therapies and advancing medical research. Through their cutting-edge research and development, Talecris is dedicated to addressing unmet medical needs and improving patient outcomes.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

6 Patents

#1 in undefined, NC

#981 in North Carolina

#44,981 in US

NC, US
NC, United States of America
Forward Citations = 46

26 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Talecris Biotherapeutics, Inc.. Retrieved from https://idiyas.com/company/talecris-biotherapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…